|
Text4baby
|
Public Education Campaign
|
ACF, AHRQ, CDC, CMS, HRSA, IHS, SAMHSA
|
NIDCR, NICHD, NIDA, NIDDK
|
Free health text messaging service for pregnant women and new mothers. Those who text "BABY" (or “BEBE” for Spanish) to 511411 receive weekly text messages, timed to their due date or their baby''s birth date through the baby’s first year. Messages, which have been vetted by both government and non-profit health experts, deal with topics such as nutrition, immunization, birth defect prevention, and oral health.
|
|
The Agricultural Health Study
|
Research Initiative
|
CDC, SAMHSA
|
NIEHS, NCI
|
The Agricultural Health Study (AHS) is a prospective study of cancer and other health outcomes (e.g. Parkinson’s disease, diabetes, thyroid disease, respiratory diseases, rheumatoid arthritis and other autoimmune disorders, and reproductive health) in a cohort of licensed pesticide applicators and their spouses from Iowa and North Carolina. The AHS began in 1993 with the goal of answering important questions about how agricultural, lifestyle and genetic factors affect the health of farming populations. The study is a collaborative effort involving investigators from National Cancer Institute, the National Institute of Environmental Health Sciences, the Environmental Protection Agency, and the National Institute for Occupational Safety and Health. More than 89,000 pesticide applicators and spouses in Iowa and North Carolina have participated in the study. Their participation has provided, and continues to provide, the data that researchers need to help the current and future generations of farmers and their families live healthier lives. Between 1993 and 1997, 52,394 licensed private pesticide applicators (mostly farmers) from Iowa and North Carolina enrolled, as did 32,345 of their spouses. The study also included 4,916 commercial pesticide applicators in Iowa in its first two phases. The average ages at enrollment were 47.1 years, 38.0 years, and 46.9 years for private applicators, commercial applicators and spouses. The study began by collecting baseline information from participants when they enrolled (1993-1997). Follow-up telephone interviews were conducted in the second (1999-2003), third phase (2005-2010), and fourth phases (2013-2015) of the study. At Phase 2, participants provided updated information on farming practices, lifestyle, and health and were asked to complete a dietary questionnaire and provide a sample of cheek cells as a source of DNA. The Phase 3 interview also updated information on farming practices, lifestyle, and health while Phase 4 focused on changes in health status. The cohort continues to be followed via linkages with cancer registries and vital statistics. Participants periodically participate in comprehensive sub-studies, including an investigation of genetic and environmental risk factors for asthma and other respiratory diseases and studies of Parkinson’s disease, neurobehavioral function and cognitive decline. Biological and environmental samples are being collected from a subset of the cohort to facilitate mechanistic studies that might explain links between pesticide and other exposures and increased risk for cancer and other conditions.
|
|
The American Congress of Obstetricians and Gynecologists (ACOG) Committee on Gynecologic Practice
|
Committee, Work group, Advisory group, or Task Force
|
CDC, FDA
|
NICHD
|
The NIH advises The American Congress of Obstetricians and Gynecologists (ACOG) Committee on Gynecologic Practice research advances that can inform gynecologic clinical practice.
|
|
The American Congress of Obstetricians and Gynecologists (ACOG) reVITALize
|
Committee, Work group, Advisory group, or Task Force
|
AHRQ, CDC, HRSA
|
NICHD
|
The American College of Obstetricians and Gynecologists and the members of the Women’s Health Registry Alliance lead the reVITALize data definition standardization efforts to harmonize definitions for the data elements used in obstetrics and gynecology. The harmonization of these definitions is critical to assure that data sharing and aggregation can provide the kind of quality information we will need to provide the best care for women and newborns now and in the future.
|
|
The Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative
|
Research Initiative
|
FDA
|
NINDS, NCCIH, NIA, NIBIB, NIDA, NIDCD, NIMH, OD/DPCPSI/OBSSR
|
The Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative is part of a new Presidential focus aimed at revolutionizing our understanding of the human brain. By accelerating the development and application of innovative technologies, researchers will be able to produce a revolutionary new dynamic picture of the brain that, for the first time, shows how individual cells and complex neural circuits interact in both time and space. Long desired by researchers seeking new ways to treat, cure, and even prevent brain disorders, this picture will fill major gaps in our current knowledge and provide unprecedented opportunities for exploring exactly how the brain enables the human body to record, process, utilize, store, and retrieve vast quantities of information, all at the speed of thought.
|
|
The Critical Path Institute (C-Path) International Neonatal Consortia (INC)
|
Committee, Work group, Advisory group, or Task Force
|
FDA
|
NICHD, NHLBI
|
The International Neonatal Consortium (INC) is a coalition of industry, academia, patient representatives, the FDA, the European Medicines Agency (EMA), other governmental agencies, professional organizations, foundations, and the Critical Path Institute (C-Path) that will focus on accelerating the development of safe and effective treatments for neonates.
|
|
The Critical Path Institute (C-Path) Global Pediatrics Trials Consortium
|
Committee, Work group, Advisory group, or Task Force
|
FDA
|
NICHD
|
The Critical Path Institute (C-Path), a pioneering non-profit organization dedicated to accelerating the pace and reducing the costs of medical product development by facilitating unique partnerships among a wide range of stakeholders, has formed a new consortium, the Global Pediatric Clinical Trials Network Pre-Launch Consortium (“Pre-Launch Consortium”).
According to Dr. Janet Woodcock, Director of the U.S. Food and Drug Administration’s (FDA) Center for Drug Evaluation and Research (CDER), “Health care providers must have high-quality, reliable data to inform treatment decisions for their pediatric patients. C-Path has leveraged its expertise and stakeholders to support the development of a first-of-its-kind pediatric clinical trial network. The Pre-Launch Consortium signals an important step toward efficient and sustainable pediatric data collection and development of better treatments for children. I strongly support this effort and look forward to working with this global consortium.”
The mission of the Pre-Launch Consortium will be the formation of an independent non-profit entity that will operate a novel global pediatric clinical trials network (“Network”). The Pre-Launch Consortium will establish the Network, create its organizational and operating framework, and identify its leadership team. This work will involve collaborators from academia, government, scientific, and regulatory agencies, industry, foundations, child health advocacy groups, and other important stakeholders.
|
|
The Effect of Various Drugs on the Retina
|
Research Initiative
|
FDA
|
NEI
|
Using powerful in vivo imaging technology, it is possible to view the retina at the cellular level. This collaboration seeks to monitor changes to the retina for drugs that are known to cross the blood/retina barrier to better understand possible toxicity.
|
|
The Environmental Determinants of Diabetes in the Young (TEDDY)
|
Research Initiative
|
CDC
|
NIDDK, NIAID, NICHD, NIEHS
|
This consortium is organizing international efforts to identify infectious agents, dietary factors, or other environmental factors that trigger type 1 diabetes in genetically susceptible people. The study enrolled over 8,000 newborns and is following them for 15 years to identify environmental triggers of type 1 diabetes.
|
|
The Epidemiology of Burkitt Lymphoma in East-African Children and Minors (EMBLEM)
|
Research Initiative
|
CDC
|
NCI
|
EMBLEM provides a unique infrastructure to obtain valuable data and samples to study Burkitt’s lymphoma (BL) epidemiology. Study data will help characterize or investigate: 1. The association of malaria-resistance genes with endemic BL. 2. Host genetic polymorphisms associated with BL using genome-wide association methods. 3. The role of the Epstein-Barr virus (EBV) genetic variants in endemic BL. 4. The role of malaria immunology and phenotype of inflammation in BL. 5. The complexity of coinfection with different P. falciparum malaria genotypes in BL. 6. The interaction between helminthic parasites, HIV, malaria, and EBV in BL. 7. The immunohistochemistry and molecular pathology of BL. 8. The impact of malaria, helminthic parasites, and HIV on childhood BL.
|